Surface antigens and potential virulence factors from parasites detected by comparative genomics of perfect amino acid repeats-2

<p><b>Copyright information:</b></p><p>Taken from "Surface antigens and potential virulence factors from parasites detected by comparative genomics of perfect amino acid repeats"</p><p>http://www.proteomesci.com/content/5/1/20</p><p>Proteome Science 2007;5():20-20.</p><p>Published online 20 Dec 2007</p><p>PMCID:PMC2254594.</p><p></p> the remainders of the respective proteomes. Bars indicate the median. The organism with 30% of asparagines in the repeats in N-glycosylation consensus is

Surface antigens and potential virulence factors from parasites detected by comparative genomics of perfect amino acid repeats-0

<p><b>Copyright information:</b></p><p>Taken from "Surface antigens and potential virulence factors from parasites detected by comparative genomics of perfect amino acid repeats"</p><p>http://www.proteomesci.com/content/5/1/20</p><p>Proteome Science 2007;5():20-20.</p><p>Published online 20 Dec 2007</p><p>PMCID:PMC2254594.</p><p></p>s. Ag, ; At, ; Br, ; Ce, ; Dd, ; Dm, ; Hs, ; Kl, ; Mm, ; Rn, ; Sc, ; Sp, ; Yl, ; Ch, ; Cn, ; Ec, ; Eh, ; Gd, ; Lm, ; Pf, ; Ta, ; Tb, ; Tp, ; r, Spearman coefficient

Surface antigens and potential virulence factors from parasites detected by comparative genomics of perfect amino acid repeats-3

<p><b>Copyright information:</b></p><p>Taken from "Surface antigens and potential virulence factors from parasites detected by comparative genomics of perfect amino acid repeats"</p><p>http://www.proteomesci.com/content/5/1/20</p><p>Proteome Science 2007;5():20-20.</p><p>Published online 20 Dec 2007</p><p>PMCID:PMC2254594.</p><p></p> data are stored in a database that is accessible on-line [44] via the depicted interface (bottom). This allows user-defined Boolean queries for repeat-containing surface proteins

<i>In vitro</i> activity against <i>T</i>. <i>cruzi</i> in IC₅₀ (μM) of compounds fulfilling hit criteria.

<p>^a<i>T</i>. <i>cruzi</i>, strain Tulahuen C4, intracellular amastigotes.</p><p>^bCytotoxicity on L6 cells.</p><p>^cSelectivity index: IC₅₀ Cytotoxicity L6/ IC₅₀<i>T</i>. <i>cruzi</i>.</p><p>IC₅₀ values are means of two independent assays, which varied < ±50%.</p><p><i>In vitro</i> activity against <i>T</i>. <i>cruzi</i> in IC₅₀ (μM) of compounds fulfilling hit criteria.</p

Final Report of the Evaluation of the Teaching and Learning Technology Programme

<p>^<i>a</i><i>L</i>. <i>don</i>. axen.: axenic amastigotes of <i>L</i>. <i>donovani</i>, strain MHOM-ET-67/L82.</p><p>^<i>b</i><i>L</i>. <i>don</i>. intracell: intracellular amastigotes of <i>L</i>. <i>donovani</i> strain MHOM-ET-67/L82.</p><p>^cCytotoxicity on macrophages infected with <i>L</i>. <i>donovani</i>.</p><p>^dCytotoxicity on peritoneal mouse macrophages.</p><p>^eSelectivity index: IC₅₀ Cytotoxicity macrophages/ IC₅₀<i>L</i>. <i>donovani</i>. IC₅₀ values are means of two independent assays, which varied < ±50%.</p><p><i>In vitro</i> activity against <i>L</i>. <i>donovani</i> in IC₅₀ (μM) of compounds fulfilling hit criteria.</p

DataSheet_2_Incomplete Plasmodium falciparum growth inhibition following piperaquine treatment translates into increased parasite viability in the in vitro parasite reduction ratio assay.pdf

Antimalarial resistance to the first-line partner drug piperaquine (PPQ) threatens the effectiveness of artemisinin-based combination therapy. In vitro piperaquine resistance is characterized by incomplete growth inhibition, i.e. increased parasite growth at higher drug concentrations. However, the 50% inhibitory concentrations (IC50) remain relatively stable across parasite lines. Measuring parasite viability of a drug-resistant Cambodian Plasmodium falciparum isolate in a parasite reduction ratio (PRR) assay helped to better understand the resistance phenotype towards PPQ. In this parasite isolate, incomplete growth inhibition translated to only a 2.5-fold increase in IC50 but a dramatic decrease of parasite killing in the PRR assay. Hence, this pilot study reveals the potential of in vitro parasite viability assays as an important, additional tool when it comes to guiding decision-making in preclinical drug development and post approval. To the best of our knowledge, this is the first time that a compound was tested against a drug-resistant parasite in the in vitro PRR assay.</p